

CASE REPORT

Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient

Shunichi Saito¹ | Gouji Toyokawa¹ | Seiya Momosaki² | Yuka Kozuma¹ |
Fumihiko Shoji¹ | Koji Yamazaki¹ | Sadanori Takeo¹

¹Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan

²Department of Pathology, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan

Correspondence

Koji Yamazaki, Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan.
Email: yamakan521@gmail.com

Abstract

Immune checkpoint inhibitors with chemotherapy have been shown to exhibit remarkable efficacy for advanced non-small-cell lung carcinoma and are under investigation as an induction therapy. However, the significance of preoperative therapy with pembrolizumab + chemotherapy for surgically resectable non-small-cell lung carcinoma still remains unclear. Here, we report a case of stage IIIB non-small-cell lung carcinoma that underwent salvage surgery after three cycles of pembrolizumab + carboplatin + nab-paclitaxel. Computed tomography revealed the remarkable decrease in tumor volume by 81%. A pathological examination showed that viable neoplastic cells were observed in <1% of the total tumorous lesion suggesting near pathological complete response. This case suggests that this regimen might be a good option as induction therapy for non-small-cell lung carcinoma.

KEYWORDS

Immunotherapy, lung cancer, neoadjuvant therapy, salvage surgery

INTRODUCTION

Immune checkpoint inhibitors (ICIs) are under investigation in the neoadjuvant setting. Several trials suggested that neoadjuvant ICI with chemotherapy exhibits remarkable efficacy for non-small-cell lung carcinoma (NSCLC); however, significance of the preoperative pembrolizumab with chemotherapy has yet to be clarified.¹⁻⁴ We report a case of a patient with locally advanced NSCLC who was successfully treated with surgical resection following pembrolizumab + carboplatin + nab-paclitaxel.

CASE REPORT

The patient was a 50-year-old man with a 32-pack/year smoking history. Chest X-ray of the medical check-up showed a mass shadow in the left upper lung field without any chief complaints (Figure 1(a)) without any pain in the chest and back, and the patient was referred to our hospital. Laboratory examinations revealed remarkable elevation of

the serum level of carcinoembryonic antigen (CEA; 1253.2 ng/mL). Chest computed tomography (CT) revealed a huge mass shadow of 132 mm in size (Figure 1(b)), in the left upper lobe with invasion into the lower lobe and main pulmonary artery. The hilar and mediastinal lymph nodes were also swollen. Positron emission tomography/CT revealed a high uptake in the mass, with a maximum standardized uptake value of 19.85 (Figure 1(c)). The patient underwent transbronchial biopsy and was diagnosed with NSCLC (cT4N2M0, cStage IIIB; Figure 2(a)). No genetic alterations were identified in epidermal growth factor receptor, anaplastic lymphoma kinase, or c-ROS oncogene 1. Two percent of the tumor cells exhibited the expression of programmed death-ligand 1 (PD-L1; 22C3; Figure 2(b)). Carboplatin + nab-paclitaxel + pembrolizumab were administered. During the second cycle, an adverse event (neutropenia: grade three) occurred and the patient could not receive nab-paclitaxel on day 15. After the second cycle, the patient's serum level of CEA decreased to 202.6 ng/mL. After the administration of pembrolizumab in the third cycle, an immune-related adverse event (infusion reaction: grade 2)




FIGURE 1 Chest X-ray revealed a mass shadow in the left upper lung field (a). Chest computed tomography (CT) revealed a huge mass shadow, measuring 132 mm in size, in the left upper lobe with invasion into the lower lobe and main pulmonary artery (b). Positron emission tomography/CT revealed an avid uptake in the mass, with a maximum standardized uptake value of 19.85 (c). After three cycles of carboplatin + nab-paclitaxel + pembrolizumab, chest X-ray revealed that the mass shadow in the left upper lung field had decreased in size (d), and CT revealed that the mass shadow reduced to 104 mm in size (−21%: stable disease) (e). Scale bar: 1.0 cm

occurred and we judged that drug therapy could not be continued. After the third cycle, laboratory examinations revealed that the patient's serum level of CEA had decreased to 20.8 ng/mL. CT revealed that the mass shadow was reduced to 104 mm in size (−21%: stable disease) and three-dimensional CT showed a remarkable decrease in tumor volume from 448 859 to 85 081 mm³ (−81%). No distant metastasis was present. The patient's good physical capacity, including his pulmonary function, suggested that he could undergo left pneumonectomy. Left pneumonectomy with open thoracotomy was electively performed in combination with the resection of the parietal pleura because of adhesion between the left upper lung and parietal pleura (Figure 2(c)). There was adhesion between parietal pleura, aorta, and left upper lung without fibrosis and necrosis of vessels and the bronchi, although we did not encounter any dilemmas in managing with hilar adhesions/dense fibrosis. The hilar and mediastinal lymph nodes were also dissected. The postoperative course was uneventful with no postoperative complications. Pneumonectomy had an insignificant effect on the patient's quality of life. The tumorous lesion in the left upper lung exhibited massive necrosis, fibrosis with hyalinization and inflammation. Viable neoplastic cells were observed in <1% of the total tumorous lesion, suggesting a near pathological complete response (pCR; Figure 2(d), arrow). In addition, no viable cells were identified in the dissected lymph nodes. After surgery, a laboratory examination revealed a further

decrease in CEA (1.3 ng/mL; Figure 3). Because of the occurrence of an infusion reaction, we decided to follow-up without postoperative therapy. Twelve months have passed without recurrence.

DISCUSSION

ICIs are generally administered to patients with advanced-stage NSCLC and their significance in induction therapy is under investigation.^{5–10} Forde et al. reported that neoadjuvant nivolumab therapy led to a major pathological response (MPR) in 9 of 20 patients (45%) and a pCR in 3 of 20 patients (15%).¹ Furthermore, neoadjuvant therapy with atezolizumab + carboplatin + nab-paclitaxel was tested in patients with resectable NSCLC and among 22 patients, 12 (54.5%) and 7 patients (32%) demonstrated an MPR and pCR, respectively.³ Therefore, ICI + chemotherapy may have a remarkable efficacy as induction therapy for resectable NSCLC, although the survival benefits are yet to be determined. Some studies showed that pCR after neoadjuvant chemotherapy brings long overall survival for the patients with NSCLC.^{11–13} Pembrolizumab and chemotherapy are also being examined in patients with resectable NSCLC, but the result has not been reported (NCT03425643).

The present case was initially diagnosed as stage IIIB NSCLC and pembrolizumab + carboplatin + nab-paclitaxel

FIGURE 2 The pathological examination of a transbronchial biopsy specimen revealed non-small-cell lung carcinoma (NSCLC) (a), and 2% of the tumor cells expressed programmed death-ligand 1 (22C3) (b). The patient underwent left pneumonectomy combined with the resection of the parietal pleura (c). The tumorous lesion in the left upper lung exhibited massive necrosis, fibrosis with hyalinization and inflammation. Viable neoplastic cells were observed in <1% of the total tumorous lesion (d) (arrow)





FIGURE 3 Changes in carcinoembryonic antigen. CEA, carcinoembryonic antigen; CBDCA, carboplatin; nab-PTX, nab-paclitaxel



were administrated. Paz-Ares et al. reported that the addition of pembrolizumab to standard chemotherapy with carboplatin and either paclitaxel or nab-paclitaxel, in comparison to chemotherapy alone, prolonged median overall survival by 4.6 months (15.9 months vs. 11.3 months) and median progression-free survival by 1.6 months (6.4 months vs. 4.8 months) in patients with untreated metastatic squamous NSCLC.¹⁴ Because of the immune-related toxicity, we considered that it was not possible to

continue this regimen any further and performed salvage surgery. The achievement of a near pCR with pembrolizumab with carboplatin + nab-paclitaxel indicates that this combination therapy might be a good option for induction therapy for NSCLC, although this regimen is not currently being investigated for this application. In summary, we report the case of a patient with NSCLC who was successfully treated with carboplatin + nab-paclitaxel + pembrolizumab followed by salvage surgery.

ACKNOWLEDGMENTS

We thank Brian Quinn for his critical comments on the manuscript. The authors have no sources of funding for the report.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

REFERENCES

1. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. *N Engl J Med*. 2018;378:1976–86.
2. Uprety D, Mandrekar SJ, Wigle D, Roden AC, Adjei AA. Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches. *J Thorac Oncol*. 2020;15:1281–97.
3. Shu CA, Gainor JF, Awad MM, Chiuhan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2020;6:786–95.
4. Provencio M, Nadal E, Insa A, Garcia-Campelo R, Casal Rubio J, Domine M, et al. NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell lung cancer (NSCLC): a phase II multicenter exploratory study-final data of patients who underwent surgical assessment. *J Clin Oncol*. 2019;37(15_suppl):8509.
5. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*. 2018;378:2078–92.
6. Reck M, Rodríguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. *J Clin Oncol*. 2019;37:537–46.
7. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*. 2015;373:1627–39.
8. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*. 2015;373:123–35.
9. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med*. 2018;378:2288–301.
10. Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. *J Thorac Oncol*. 2009;4:1380–8.
11. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. *J Thorac Oncol*. 2012;7:825–32.
12. Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. *Chest*. 2001;120:1584–91.
13. Melek H, Çetinkaya G, Özer E, Yentürk E, Sevinç TE, Bayram AS, et al. Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system? *Eur J Cardiothorac Surg*. 2019;56:604–11.
14. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med*. 2018;379:2040–51.

How to cite this article: Saito S, Toyokawa G, Momosaki S, et al. Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient. *Thorac Cancer*. 2021;12:2217–2220. <https://doi.org/10.1111/1759-7714.14051>